243
Participants
Start Date
September 14, 2016
Primary Completion Date
March 27, 2023
Study Completion Date
August 2, 2023
ALKS 4230
Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period
ALKS 4230 + pembrolizumab
IV infusion of ALKS 4230 over 30 minutes given daily for 5 consecutive days followed by an off-treatment period; pembrolizumab administered IV once with ALKS 4230 on the first day of each cycle
Mural Oncology Investigational Site, Brussels
Mural Oncology Investigational Site, Waratah
Mural Oncology Investgational Site, Albury
Mural Oncology Investigational Site, Barcelona
Mural Oncology Investigational Site, Kortrijk
Mural Oncology Investigational Site, New York
Mural Oncology Investigational Site, Buffalo
Mural Oncology Investigational Site, Fairfax
Mural Oncology Investigational Site, Madrid
Mural Oncology Investigational Site, Madrid
Mural Oncology Investigational Site, Madrid
Mural Oncology Investigational Site, Madrid
Mural Oncology Investigational Site, Tampa
Mural Oncology Investigational Site, Port Saint Lucie
Mural Oncology Investigational Site, Daejeon
Mural Oncology Investigational Site, Lexington
Mural Oncology Investigational Site, Cleveland
Mural Oncology Investigational Site, Valencia
Mural Oncology Investigational Site, Detroit
Mural Oncology Investigational Site, Dallas
Mural Oncology Investigational Site, Denver
Mural Oncology Investigational Site, Spokane
Mural Oncology Investigational Site, Boston
Mural Oncology Investigational Site, Edmonton
Mural Oncology Investigational Site, Hamilton
Alkermes Investigational Site, Toronto
Mural Oncology Investigational Site, Montreal
Mural Oncology Investigational Site, Québec
Mural Oncology Investigational Site, Skorzewo
Mural Oncology Investigational Site, Seoul
Mural Oncology Investigational Site, Seoul
Lead Sponsor
Mural Oncology, Inc
INDUSTRY